First Time Loading...

ImmuCell Corp
NASDAQ:ICCC

Watchlist Manager
ImmuCell Corp Logo
ImmuCell Corp
NASDAQ:ICCC
Watchlist
Price: 5.14 USD 0.78%
Updated: Apr 29, 2024

Relative Value

The Relative Value of one ICCC stock under the Base Case scenario is 7.68 USD. Compared to the current market price of 5.14 USD, ImmuCell Corp is Undervalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ICCC Relative Value
Base Case
7.68 USD
Undervaluation 33%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
90
vs Industry
79
Median 3Y
3
Median 5Y
2.9
Industry
8.1
vs History
vs Industry
Median 3Y
-7.1
Median 5Y
-21.1
Industry
26.2
vs History
vs Industry
1
Median 3Y
-6.9
Median 5Y
30.5
Industry
22.6
vs History
vs Industry
Median 3Y
-7.9
Median 5Y
-15
Industry
21.3
vs History
44
vs Industry
52
Median 3Y
1.9
Median 5Y
1.6
Industry
2.5
vs History
66
vs Industry
64
Median 3Y
3.1
Median 5Y
3
Industry
7.3
vs History
9
vs Industry
35
Median 3Y
9.3
Median 5Y
7.2
Industry
9.1
vs History
vs Industry
10
Median 3Y
22.3
Median 5Y
30.2
Industry
4.4
vs History
vs Industry
1
Median 3Y
-8.8
Median 5Y
-30.4
Industry
4.3
vs History
vs Industry
1
Median 3Y
-8.3
Median 5Y
29.8
Industry
5.4
vs History
vs Industry
Median 3Y
-20.4
Median 5Y
-21.6
Industry
3.2
vs History
79
vs Industry
58
Median 3Y
1.6
Median 5Y
1.4
Industry
5

Multiples Across Competitors

ICCC Competitors Multiples
ImmuCell Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
ImmuCell Corp
NASDAQ:ICCC
39.8m USD 2.3 -6.9 -16.3 -8.6
US
Abbvie Inc
NYSE:ABBV
280.4B USD 5.2 58.2 12.7 19.3
US
Amgen Inc
NASDAQ:AMGN
146.3B USD 5.2 21.7 16.2 24.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 10.3 28.2 22.6 23.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
97.9B USD 7.5 24.8 16.4 18
AU
CSL Ltd
ASX:CSL
132.9B AUD 6.1 35.1 21.3 26.4
US
Gilead Sciences Inc
NASDAQ:GILD
82.8B USD 3.1 14.6 8 10.3
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Moderna Inc
NASDAQ:MRNA
42.6B USD 6.2 -9 -9.6 -8.2
US
Biogen Inc
NASDAQ:BIIB
31.6B USD 3.2 27.2 14.7 18.2
IE
Horizon Therapeutics PLC
NASDAQ:HZNP
26.6B USD 7.3 60.8 27.9 47
EV/EBITDA Multiple
EBITDA Growth
US
ImmuCell Corp
NASDAQ:ICCC
Average EV/EBITDA: 17.5
Negative Multiple: -16.3
N/A
US
Abbvie Inc
NYSE:ABBV
12.7
26%
US
Amgen Inc
NASDAQ:AMGN
16.2
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
59%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
50%
AU
CSL Ltd
ASX:CSL
21.3
54%
US
Gilead Sciences Inc
NASDAQ:GILD
8
18%
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -9.6 N/A
US
Biogen Inc
NASDAQ:BIIB
14.7
67%
IE
Horizon Therapeutics PLC
NASDAQ:HZNP
27.9
83%

See Also

Discover More